Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HPGD | P15428 | 7/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.53 |
| ▸ | CTSV | O60911 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130919 | 0.99 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL16237897 | 0.99 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL301567 | 0.99 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL26993708 | 0.99 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29365383 | 0.99 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL29355024 | 0.86 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL17739377 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL20604049 | 0.84 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8537338 | 0.84 | CYP2D6 (0.66) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL18229465 | 0.83 | OXER1 (0.64) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730197-B1 | METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA | HAPTOGEN LTD (GB) | 2012-03-07 | — | — | EP | claimed |
| US-20110027280-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2011-02-03 | — | — | US | claimed |
| US-20070218058-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. POLWARTH BUILDING (GB) | 2007-09-20 | — | — | US | claimed |
| EP-1730197-A2 | METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA | Haptogen Ltd (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005094883-A2 | METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA | HAPTOGEN LTD (GB) | 2005-10-13 | — | — | WO | claimed |
| US-20130011400-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2013-01-10 | — | — | US | disclosed |
| US-20110027280-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2011-02-03 | — | — | US | disclosed |
| US-20110027280-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. (GB) | 2011-02-03 | — | — | US | disclosed |
| EP-2261260-A2 | Methods for inducing autolysis in infectious bacteria | Haptogen Ltd (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20070218058-A1 | Methods For Inducing Autolysis In Infectious Bacteria | HAPTOGEN LTD. POLWARTH BUILDING (GB) | 2007-09-20 | — | — | US | disclosed |
| EP-1730197-A2 | METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA | Haptogen Ltd (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094883-A2 | METHODS FOR INDUCING AUTOLYSIS IN INFECTIOUS BACTERIA | HAPTOGEN LTD (GB) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011400-A1 | Methods For Inducing Autolysis In Infectious Bacteria | CFTR, ENPP2, BAD | KDM4E 4823/4885ALDH1A1 4798/4885HPGD 3047/4885 |
| US-20110027280-A1 | Methods For Inducing Autolysis In Infectious Bacteria | CFTR, ENPP2, BAD | KDM4E 4823/4885ALDH1A1 4798/4885HPGD 3047/4885 |
| US-20070218058-A1 | Methods For Inducing Autolysis In Infectious Bacteria | CFTR, BAD, ENPP2 | KDM4E 4846/4885ALDH1A1 4804/4885HPGD 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.